NLS Bioarctic

The company will receive a milestone payment from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with BAN2401 in early Alzheimer´s disease. Eisai is responsible for the clinical development of BAN2401, including this confirmatory Phase 3 study, and BioArctic is entitled […]

The US Patent and Trademark Office (USPTO) published an Issue of Notification of granting the company’s patent application for a method with the medical device, which is one of the components in the product candidate SC0806. The notification states that the US patent will be granted and enters into force on February 20, 2018. The patent […]

BioArctic announces that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017. The European patent EP2539366 covers the monoclonal antibody candidate BAN0805 per se, intended for treatment of neurodegenerative disorders, including Parkinson’s disease. Validated national patents will expire on February 25, […]

Karolinska Development announces that its portfolio company BioArctic has entered into a strategically important collaboration with AbbVie, a global biopharmaceutical company, to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications. Parkinson’s disease is the second most-common neurological disease, affecting more than 10 million […]

Gunilla Osswald has been appointed as the company’s new CEO. Osswald joined BioArctic in February 2013 as Deputy CEO. She was recruited from AstraZeneca where she was working as VP for Neurodegenerative disorder projects. According to Bioarctic, the new CEO has vast experience in leadership and drug development in neuroscience. In a press release from the […]